BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1149 related articles for article (PubMed ID: 18974200)

  • 21. Interactions between sphingosine-1-phosphate and vascular endothelial growth factor signalling in ML-1 follicular thyroid carcinoma cells.
    Balthasar S; Bergelin N; Löf C; Vainio M; Andersson S; Törnquist K
    Endocr Relat Cancer; 2008 Jun; 15(2):521-34. PubMed ID: 18509004
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A natural anti-inflammatory enone fatty acid inhibits angiogenesis by attenuating nuclear factor-κB signaling in vascular endothelial cells.
    Furuno A; Watari K; Nakamura M; Fukunaga Y; Jung JH; Ono M
    Int J Oncol; 2011 Feb; 38(2):493-501. PubMed ID: 21132269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Albendazole inhibits endothelial cell migration, tube formation, vasopermeability, VEGF receptor-2 expression and suppresses retinal neovascularization in ROP model of angiogenesis.
    Pourgholami MH; Khachigian LM; Fahmy RG; Badar S; Wang L; Chu SW; Morris DL
    Biochem Biophys Res Commun; 2010 Jul; 397(4):729-34. PubMed ID: 20537982
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
    Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
    Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A selective and oral small molecule inhibitor of vascular epithelial growth factor receptor (VEGFR)-2 and VEGFR-1 inhibits neovascularization and vascular permeability.
    Patel N; Sun L; Moshinsky D; Chen H; Leahy KM; Le P; Moss KG; Wang X; Rice A; Tam D; Laird AD; Yu X; Zhang Q; Tang C; McMahon G; Howlett A
    J Pharmacol Exp Ther; 2003 Sep; 306(3):838-45. PubMed ID: 12766257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different cascades in the signaling pathway of two vascular endothelial growth factor (VEGF) receptors for the VEGF-mediated murine hepatocellular carcinoma development.
    Yoshiji H; Noguchi R; Kuriyama S; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Uemura M; Fukui H
    Oncol Rep; 2005 May; 13(5):853-7. PubMed ID: 15809749
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts.
    Davis DW; Inoue K; Dinney CP; Hicklin DJ; Abbruzzese JL; McConkey DJ
    Cancer Res; 2004 Jul; 64(13):4601-10. PubMed ID: 15231672
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activation of fractalkine/CX3CR1 by vascular endothelial cells induces angiogenesis through VEGF-A/KDR and reverses hindlimb ischaemia.
    Ryu J; Lee CW; Hong KH; Shin JA; Lim SH; Park CS; Shim J; Nam KB; Choi KJ; Kim YH; Han KH
    Cardiovasc Res; 2008 May; 78(2):333-40. PubMed ID: 18006432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor associated with tumor cell proliferation in canine cutaneous squamous cell carcinomas and trichoepitheliomas.
    Al-Dissi AN; Haines DM; Singh B; Kidney BA
    Vet Pathol; 2007 Nov; 44(6):823-30. PubMed ID: 18039895
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1.
    Hazarika S; Dokun AO; Li Y; Popel AS; Kontos CD; Annex BH
    Circ Res; 2007 Oct; 101(9):948-56. PubMed ID: 17823371
    [TBL] [Abstract][Full Text] [Related]  

  • 32. VGA1155, a novel binding antagonist of VEGF, inhibits angiogenesis in vitro and in vivo.
    Ueda Y; Yamagishi T; Ikeya H; Hirayama N; Itokawa T; Aozuka Y; Samata K; Nakaike S; Tanaka M; Ono M; Saiki I
    Anticancer Res; 2004; 24(5A):3009-17. PubMed ID: 15517909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro.
    Weigand M; Hantel P; Kreienberg R; Waltenberger J
    Angiogenesis; 2005; 8(3):197-204. PubMed ID: 16328160
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adrenomedullin stimulates angiogenic response in cultured human vascular endothelial cells: involvement of the vascular endothelial growth factor receptor 2.
    Guidolin D; Albertin G; Spinazzi R; Sorato E; Mascarin A; Cavallo D; Antonello M; Ribatti D
    Peptides; 2008 Nov; 29(11):2013-23. PubMed ID: 18692535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of vascular endothelial growth factor-induced angiogenesis by scopoletin through interrupting the autophosphorylation of VEGF receptor 2 and its downstream signaling pathways.
    Pan R; Dai Y; Gao XH; Lu D; Xia YF
    Vascul Pharmacol; 2011; 54(1-2):18-28. PubMed ID: 21078410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complex formation between tissue transglutaminase II (tTG) and vascular endothelial growth factor receptor 2 (VEGFR-2): proposed mechanism for modulation of endothelial cell response to VEGF.
    Dardik R; Inbal A
    Exp Cell Res; 2006 Oct; 312(16):2973-82. PubMed ID: 16914140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiangiogenic properties of gold nanoparticles.
    Mukherjee P; Bhattacharya R; Wang P; Wang L; Basu S; Nagy JA; Atala A; Mukhopadhyay D; Soker S
    Clin Cancer Res; 2005 May; 11(9):3530-4. PubMed ID: 15867256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.
    Ebos JM; Lee CR; Bogdanovic E; Alami J; Van Slyke P; Francia G; Xu P; Mutsaers AJ; Dumont DJ; Kerbel RS
    Cancer Res; 2008 Jan; 68(2):521-9. PubMed ID: 18199548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 inhibitors.
    Kuo GH; Wang A; Emanuel S; Deangelis A; Zhang R; Connolly PJ; Murray WV; Gruninger RH; Sechler J; Fuentes-Pesquera A; Johnson D; Middleton SA; Jolliffe L; Chen X
    J Med Chem; 2005 Mar; 48(6):1886-900. PubMed ID: 15771433
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of vascular endothelial growth factor receptors on tumor cells in head and neck squamous cell carcinoma.
    Lalla RV; Boisoneau DS; Spiro JD; Kreutzer DL
    Arch Otolaryngol Head Neck Surg; 2003 Aug; 129(8):882-8. PubMed ID: 12925349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 58.